A M Bayoumi1, D A Redelmeier. 1. Department of Medicine, University of Toronto, Canada. ahmed.bayoumi@utoronto.ca
Abstract
BACKGROUND: Quality of life is measured as utilities for cost-effectiveness analyses. OBJECTIVE: To test the adequacy of three common utility elicitation methods for individuals with Human Immunodeficiency Virus (HIV) disease. MEASUREMENTS: HIV-positive participants (n = 75) rated three standardized health states (symptomatic HIV infection, minor AIDS defining illness, and major AIDS defining illness) with two utility elicitation methods (Standard Gamble [SG], and Time Trade-off [TTO]) and one value method (Visual Analog [VA]). Participants also rated their own health with one utility method (Health Utilities Index [HUI]) and one conventional quality of life method (Medical Outcomes Study--HIV Health Survey [MOS-HIV]). RESULTS: For all states, SG and TTO scores ranged from near 0.00 (equivalent to death) to 1.00 (best possible quality of life). Mean scores for symptomatic HIV were similar with the SG (0.80) and TTO (0.81) but higher than with the VA (0.70). Similar results were observed for minor AIDS defining illnesses (0.65, 0.65, 0.46 respectively) and major AIDS defining illnesses (0.42, 0.44, 0.25 respectively). Discrepant SG and TTO scores were observed in many individuals and were not explained by demographic characteristics. As expected, HUI scores of an individual's own health were related to the disease state. Four of ten MOS-HIV subscales (overall health, physical functioning, role functioning, and pain) were also related to disease state. HUI scores were correlated with the MOS-HIV score for overall health and for all MOS-HIV subscales except health transition. CONCLUSIONS: Mean utility scores for HIV-related health states elicited by the Standard Gamble and Time Trade-off were similar but a large degree of individual variation persists. Economic methods provide imprecise estimates of the quality of life associated with HIV infection.
BACKGROUND: Quality of life is measured as utilities for cost-effectiveness analyses. OBJECTIVE: To test the adequacy of three common utility elicitation methods for individuals with Human Immunodeficiency Virus (HIV) disease. MEASUREMENTS: HIV-positive participants (n = 75) rated three standardized health states (symptomatic HIV infection, minor AIDS defining illness, and major AIDS defining illness) with two utility elicitation methods (Standard Gamble [SG], and Time Trade-off [TTO]) and one value method (Visual Analog [VA]). Participants also rated their own health with one utility method (Health Utilities Index [HUI]) and one conventional quality of life method (Medical Outcomes Study--HIV Health Survey [MOS-HIV]). RESULTS: For all states, SG and TTO scores ranged from near 0.00 (equivalent to death) to 1.00 (best possible quality of life). Mean scores for symptomatic HIV were similar with the SG (0.80) and TTO (0.81) but higher than with the VA (0.70). Similar results were observed for minor AIDS defining illnesses (0.65, 0.65, 0.46 respectively) and major AIDS defining illnesses (0.42, 0.44, 0.25 respectively). Discrepant SG and TTO scores were observed in many individuals and were not explained by demographic characteristics. As expected, HUI scores of an individual's own health were related to the disease state. Four of ten MOS-HIV subscales (overall health, physical functioning, role functioning, and pain) were also related to disease state. HUI scores were correlated with the MOS-HIV score for overall health and for all MOS-HIV subscales except health transition. CONCLUSIONS: Mean utility scores for HIV-related health states elicited by the Standard Gamble and Time Trade-off were similar but a large degree of individual variation persists. Economic methods provide imprecise estimates of the quality of life associated with HIV infection.
Authors: A W Wu; H R Rubin; W C Mathews; J E Ware; L T Brysk; W D Hardy; S A Bozzette; S A Spector; D D Richman Journal: Med Care Date: 1991-08 Impact factor: 2.983
Authors: Shyoko Honiden; Vandana Sundaram; Robert F Nease; Mark Holodniy; Laura C Lazzeroni; Andrew Zolopa; Douglas K Owens Journal: Qual Life Res Date: 2006-02 Impact factor: 4.147
Authors: Bohdan Nosyk; Huiying Sun; Nick Bansback; Daphne P Guh; Xin Li; Paul Barnett; Ahmed Bayoumi; Susan Griffin; Vilija Joyce; Mark Holodniy; Doug K Owens; Aslam H Anis Journal: Qual Life Res Date: 2009-06-27 Impact factor: 4.147
Authors: Darren J Clayson; Diane J Wild; Paul Quarterman; Isabelle Duprat-Lomon; Maria Kubin; Stephen Joel Coons Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981
Authors: I D Coulter; K C Heslin; M Marcus; R D Hays; J Freed; C Der-Martirosia; N Guzmán-Becerra; W E Cunningham; R M Andersen; M F Shapiro Journal: Qual Life Res Date: 2002-02 Impact factor: 4.147
Authors: Karen Y Chung; Gebremedhin B Gebretekle; Andrew Howard; Eleanor Pullenayegum; Mekonen Eshete; Christopher R Forrest; Beate Sander Journal: JAMA Netw Open Date: 2022-07-01